Next Article in Journal
Synthesis, Biological Evaluation, and Modeling of Dimeric PPI Analogues as Novel DNA Minor Groove Binders
Next Article in Special Issue
Polyanionic Drugs and Viral Oncogenesis: a Novel Approach to Control Infection, Tumor-associated Inflammation and Angiogenesis
Previous Article in Journal
Neglschisandrins C-D: Two New Dibenzocyclooctadiene Lignans from Schisandra neglecta
Previous Article in Special Issue
Progress in Drug Delivery to the Central Nervous System by the Prodrug Approach
Article Menu

Export Article

Open AccessReview
Molecules 2008, 13(5), 1156-1178;

Prodrugs in Cardiovascular Therapy

Department of Biomedical Engineering, McGill University, 3775 University Street, Montreal, QC, Canada H3A2B4
Faculty of Dentistry, McGill University, 3640 University Street, Montreal, QC, Canada, H3A 2B2
Center for Biorecognition and Biosensors, McGill Institute for Advanced Materials, 3775 University Street, Montreal, QC, Canada H3A2B4
Department of Medical Education, Seton Hall University, 400 South Orange Avenue, South Orange, NJ 07079, USA
St. Michael’s Medical Center, 111 Central Avenue, Newark, NJ 070102, USA
Author to whom correspondence should be addressed.
Received: 5 February 2008 / Revised: 14 May 2008 / Accepted: 14 May 2008 / Published: 14 May 2008
(This article belongs to the Special Issue Prodrugs)
Full-Text   |   PDF [423 KB, uploaded 18 June 2014]   |  


Prodrugs are biologically inactive derivatives of an active drug intended to solve certain problems of the parent drug such as toxicity, instability, minimal solubility and non-targeting capabilities. The majority of drugs for cardiovascular diseases undergo firstpass metabolism, resulting in drug inactivation and generation of toxic metabolites, which makes them appealing targets for prodrug design. Since prodrugs undergo a chemical reaction to form the parent drug once inside the body, this makes them very effective in controlling the release of a variety of compounds to the targeted site. This review will provide the reader with an insight on the latest developments of prodrugs that are available for treating a variety of cardiovascular diseases. In addition, we will focus on several drug delivery methodologies that have merged with the prodrug approach to provide enhanced target specificity and controlled drug release with minimal side effects. View Full-Text
Keywords: Prodrug; cardiovascular disease; drug-eluting stents; antiplatelet; antithrombin. Prodrug; cardiovascular disease; drug-eluting stents; antiplatelet; antithrombin.

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Sandros, M.G.; Sarraf, C.B.; Tabrizian, M. Prodrugs in Cardiovascular Therapy. Molecules 2008, 13, 1156-1178.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top